See more : Godrej Consumer Products Limited (GODREJCP.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Covetrus, Inc. (CVET) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Covetrus, Inc., a leading company in the Medical – Distribution industry within the Healthcare sector.
- Whetron Electronics Co.,Ltd. (6722.TWO) Income Statement Analysis – Financial Results
- Hapag-Lloyd Aktiengesellschaft (HLAG.DE) Income Statement Analysis – Financial Results
- Haci Ömer Sabanci Holding A.S. (SAHOL.IS) Income Statement Analysis – Financial Results
- ProtoSource Corporation (PSCO) Income Statement Analysis – Financial Results
- Suzhou W Deane New Power Elec (603312.SS) Income Statement Analysis – Financial Results
Covetrus, Inc. (CVET)
About Covetrus, Inc.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine. As of October 13, 2022, Covetrus, Inc. was taken private.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 4.58B | 4.34B | 3.98B | 3.78B | 3.58B | 3.35B | 2.98B |
| Cost of Revenue | 3.72B | 3.54B | 3.23B | 3.09B | 2.93B | 2.73B | 2.45B |
| Gross Profit | 858.00M | 798.00M | 749.00M | 684.11M | 652.03M | 619.91M | 530.02M |
| Gross Profit Ratio | 18.75% | 18.39% | 18.84% | 18.11% | 18.21% | 18.49% | 17.80% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 867.00M | 808.00M | 538.47M | 516.70M | 488.82M | 417.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 881.00M | 867.00M | 808.00M | 538.47M | 516.70M | 488.82M | 417.87M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 881.00M | 867.00M | 808.00M | 538.47M | 516.70M | 488.82M | 417.87M |
| Cost & Expenses | 4.60B | 4.41B | 4.04B | 3.63B | 3.44B | 3.22B | 2.87B |
| Interest Income | 0.00 | 1.00M | 7.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 32.00M | 47.00M | 56.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 200.00M | 190.00M | 176.00M | 64.10M | 59.05M | 55.45M | 50.30M |
| EBITDA | 178.00M | 211.00M | -794.00M | 201.99M | 171.43M | 153.68M | 134.89M |
| EBITDA Ratio | 3.89% | 4.86% | -19.97% | 5.35% | 4.79% | 4.58% | 4.53% |
| Operating Income | -22.00M | -69.00M | -997.00M | 137.10M | 135.32M | 123.83M | 103.81M |
| Operating Income Ratio | -0.48% | -1.59% | -25.08% | 3.63% | 3.78% | 3.69% | 3.49% |
| Total Other Income/Expenses | -32.00M | 45.00M | -32.00M | 6.08M | 3.45M | 2.97M | 4.69M |
| Income Before Tax | -54.00M | -24.00M | -1.03B | 143.18M | 138.77M | 126.79M | 108.50M |
| Income Before Tax Ratio | -1.18% | -0.55% | -25.88% | 3.79% | 3.88% | 3.78% | 3.64% |
| Income Tax Expense | 32.00M | -7.00M | -7.00M | 37.03M | 48.02M | 27.94M | 24.27M |
| Net Income | -86.00M | -19.00M | -1.02B | 100.86M | 64.35M | 70.30M | 60.32M |
| Net Income Ratio | -1.88% | -0.44% | -25.63% | 2.67% | 1.80% | 2.10% | 2.03% |
| EPS | -0.63 | -0.16 | -9.52 | 0.91 | 0.58 | 0.63 | 0.54 |
| EPS Diluted | -0.63 | -0.16 | -9.52 | 0.91 | 0.58 | 0.63 | 0.54 |
| Weighted Avg Shares Out | 137.00M | 118.00M | 107.00M | 111.19M | 111.19M | 111.19M | 111.19M |
| Weighted Avg Shares Out (Dil) | 137.00M | 118.00M | 107.00M | 111.19M | 111.19M | 111.19M | 111.19M |
G.Research Comments on Covetrus Inc's FY2020 Earnings (NASDAQ:CVET)
FY2024 Earnings Forecast for Covetrus Inc Issued By G.Research (NASDAQ:CVET)
ValuEngine Lowers Covetrus (NASDAQ:CVET) to Hold
Cubist Systematic Strategies LLC Buys 6,683 Shares of Covetrus Inc (NASDAQ:CVET)
Covetrus Inc (NASDAQ:CVET) Given Average Rating of "Hold" by Brokerages
Covetrus Inc (NASDAQ:CVET) Position Increased by Amalgamated Bank
Covetrus Inc Expected to Earn Q1 2020 Earnings of $0.09 Per Share (NASDAQ:CVET)
Credit Suisse AG Decreases Holdings in Covetrus Inc (NASDAQ:CVET)
Benzinga Pro's Stock To Watch For Tues., Mar. 24, 2020: CVET
Investors Purchase High Volume of Covetrus Call Options (NASDAQ:CVET)
Source: https://incomestatements.info
Category: Stock Reports